ABT vs COLL · P/E 25, rev $44.33B vs P/E 17, rev $181.9M
Abbott Laboratories (ABT) versus Collegium Pharmaceutical Inc (COLL) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Not investment advice. Open the ABT and COLL stock pages for the full models.
Not investment advice.